- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Interventions
- Asundexian (BAY2433334), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 108
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 10,683
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Interventions
- tanespimycin, rituximab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Kidney Transplant, Renal Failure Chronic Requiring Hemodialysis
- Interventions
- navigator
- Other
- Lead sponsor
- Catherine Sullivan
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,926 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Fort Wayne, Indiana • Lexington, Kentucky • Louisville, Kentucky + 2 more
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Drug
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Myelodysplastic Syndrome, Iron Overload
- Interventions
- Deferasirox
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
- Conditions
- Carotid Artery Disease
- Interventions
- Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Birinapant, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
- Conditions
- HIV Infections
- Interventions
- Delavirdine mesylate, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 10
- States / cities
- Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Interventions
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Vaginal Atrophy
- Interventions
- Placebo, DHEA
- Drug
- Lead sponsor
- EndoCeutics Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 32
- States / cities
- Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
- Interventions
- Efgartigimod IV, Empasiprubart IV
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Carlsbad, California • Miami, Florida • Tampa, Florida + 7 more
- Conditions
- Hematological Malignancies
- Interventions
- Magrolimab, Azacitidine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 26
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Narcolepsy With Cataplexy
- Interventions
- Xyrem
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Long Beach, California • Orange, California • Redwood City, California + 14 more
- Conditions
- Diabetic Gastroparesis
- Interventions
- Virtual Yoga
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Spinal Muscular Atrophy Type I
- Interventions
- Valproic Acid and Levocarnitine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 2 Weeks to 12 Months
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Durham, North Carolina + 3 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Lispro Injection, Humalog
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 58
- States / cities
- Anaheim, California • Fresno, California • Los Angeles, California + 52 more
- Conditions
- Overweight, Obese
- Interventions
- Blackraspberry Slurry
- Dietary Supplement
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 55 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lipoprotein Disorder
- Interventions
- LY3819469, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 19
- States / cities
- Mesa, Arizona • Pasadena, California • Santa Clarita, California + 16 more
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and Trospium Chloride Capsules
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- NVL-330
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Irvine, California • Sacramento, California • Stanford, California + 13 more
- Conditions
- Ovarian Neoplasms
- Interventions
- TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 234
- States / cities
- Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
- Conditions
- Leukemia
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 197
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
- Conditions
- Acute Adenoviral Conjunctivitis
- Interventions
- FST-100 Ophthalmic Suspension, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 13
- States / cities
- Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more